Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing off-the-shelf therapeutic cancer vaccines using its T-win platform. Its products target immunosuppressive tumor microenvironment mechanisms, aiming to activate T cells against cancer cells and suppressive cells. Focused on solid tumors like melanoma, lung, and head and neck cancers, the company seeks to transform cancer immunotherapy through innovative, immune-modulatory vaccines designed for combination treatments and broad patient applicability.
This description was generated via AI from an annual report. Updated about 1 year ago.